Breakthrough EU approval for Dupixent offers new hope for children with eosinophilic esophagitis

Breakthrough EU approval for Dupixent offers new hope for children with eosinophilic esophagitis

The European Medicines Agency (EMA) has granted approval for Dupixent, a therapy developed by Sanofi and Regeneron, to treat eosinophilic esophagitis (EoE) in children as young as one year old. This decision marks a critical step in addressing a condition that has left young patients and their families with limited options. With this approval, Dupixent […]